Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where I.M. Fuentes is active.

Publication


Featured researches published by I.M. Fuentes.


Stem Cells and Development | 2011

Analysis of the Chondrogenic Potential and Secretome of Mesenchymal Stem Cells Derived from Human Umbilical Cord Stroma

María Arufe; Alexandre De la Fuente; Jesús Mateos; I.M. Fuentes; Francisco J. de Toro; F.J. Blanco

Mesenchymal stem cells (MSCs) from umbilical cord stroma were isolated by plastic adherence and characterized by flow cytometry, looking for cells positive for OCT3/4 and SSEA-4 as well as the classic MSC markers CD44, CD73, CD90, Ki67, CD105, and CD106 and negative for CD34 and CD45. Quantitative reverse transcriptase-polymerase chain reaction analysis of the genes ALP, MEF2C, MyoD, LPL, FAB4, and AMP, characteristic for the differentiated lineages, were used to evaluate early and late differentiation of 3 germ lines. Direct chondrogenic differentiation was achieved through spheroid formation by MSCs in a chondrogenic medium and the presence of chondrogenic markers at 4, 7, 14, 28, and 46 days of culture was tested. Immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction analyses were utilized to assess the expression of collagen type I, collagen type II, and collagen type X throughout the time studied. We found expression of all the markers as early as 4 days of chondrogenic differentiation culture, with their expression increasing with time, except for collagen type I, which decreased in expression in the formed spheroids after 4 days of differentiation. The signaling role of Wnt during chondrogenic differentiation was studied by western blot. We observed that β-catenin expression decreased during the chondrogenic process. Further, a secretome study to validate our model of differentiation in vitro was performed on spheroids formed during the chondrogenesis process. Our results indicate the multipotential capacity of this source of human cells; their chondrogenic capacity could be useful for future cell therapy in articular diseases.


Scientific Reports | 2015

Influence of age on rat bone-marrow mesenchymal stem cells potential

J. Fafián-Labora; Pablo Fernández-Pernas; I.M. Fuentes; J. De Toro; N. Oreiro; S. Sangiao-Alvarellos; Jesús Mateos; M.C. Arufe

Mesenchymal stem cells promising role in cell-based therapies and tissue engineering appears to be limited due to a decline of their regenerative potential with increasing donor age. Six age groups from bone marrow mesenchymal stem cells of Wistar rats were studied (newborn, infant, young, pre-pubertal, pubertal and adult). Quantitative proteomic assay was performance by iTRAQ using an 8-plex iTRAQ labeling and the proteins differentially expressed were grouped in pluripotency, proliferative and metabolism processes. Proliferation makers, CD117 and Ki67 were measure by flow cytometry assay. Real time polymerase chain reaction analysis of pluripotency markers Rex1, Oct4, Sox2 and Nanog were done. Biological differentiation was realized using specific mediums for 14 days to induce osteogenesis, adipogenesis or chondrogenesis and immunostain analysis of differentiated cell resulting were done. Enzimoimmunoassay analysis of several enzymes as L-lactate dehydrogenase and glucose-6-phosphate isomerase were also done to validate iTRAQ data. Taking together these results indicate for the first time that mesenchymal stem cells have significant differences in their proliferative, pluripotency and metabolism profiles and those differences are age depending.


Journal of Cellular Biochemistry | 2016

3, 3′, 5-triiodo-L-thyronine Increases In Vitro Chondrogenesis of Mesenchymal Stem Cells From Human Umbilical Cord Stroma Through SRC2

Pablo Fernández-Pernas; Juan Fafián-Labora; Iván Lesende-Rodríguez; Jesús Mateos; Alexandre De la Fuente; I.M. Fuentes; Javier Santos; Fco. Blanco García; M.C. Arufe

Our group focuses on the study of mesenchymal stem cells (MSCs) from human umbilical cord stroma or Warthońs jelly and their directed differentiation toward chondrocyte‐like cells capable of regenerating damaged cartilage when transplanted into an injured joint. This study aimed to determine whether lactogenic hormone prolactin (PRL) or 3, 3′, 5‐triiodo‐L‐thyronine (T3), the active thyroid hormone, modulates chondrogenesis in our in vitro model of directed chondrogenic differentiation, and whether Wnt signalling is involved in this modulation. MSCs from human umbilical cord stroma underwent directed differentiation toward chondrocyte‐like cells by spheroid formation. The addition of T3 to the chondrogenic medium increased the expression of genes linked to chondrogenesis like collagen type 2, integrin alpha 10 beta 1, and Sox9 measured by quantitative real time polymerase chain reaction (qRT‐PCR) analysis. Levels of collagen type 2 and aggrecane analyzed by immunohistochemistry, and staining by Safranin O were increased after 14 days in spheroid culture with T3 compared to those without T3 or only with PRL. B‐catenin, Frizzled, and GSK‐3β gene expressions were significantly higher in spheroids cultured with chondrogenic medium (CM) plus T3 compared to CM alone after 14 days in culture. The increase of chondrogenic differentiation was inhibited when the cells were treated with T3 plus ML151, an inhibitor of the T3 steroid receptor. This work demonstrates, for first time, that T3 promotes differentiation towards chondrocytes‐like cells in our in vitro model, that this differentiation is mediated by steroid receptor co‐activator 2 (SRC2) and does not induce hypertrophy. J. Cell. Biochem. 117: 2097–2108, 2016.


PLOS ONE | 2017

CD105+-mesenchymal stem cells migrate into osteoarthritis joint: an animal model

Pablo Fernández-Pernas; Iván Rodríguez-Lesende; Alexandre De la Fuente; Jesús Mateos; I.M. Fuentes; Javier De Toro; Fco J. Blanco; M.C. Arufe; Irina Kerkis

Mesenchymal stem cells are being the focus of connective tissue technology and regenerative medicine, presenting a good choice cell source for improving old and well recognized techniques of cartilage defect repair. For instance, the autologous chondrocyte transplantation using new concepts of regenerative medicine. The present study investigated the risk of xenogenicity of human synovial membrane-derived MSCs, injected into the monkeys using intravenous and intra-articular administration. The animal models used were adult monkeys Rhesus which had been injured into the left knee to create an Osteoarthritis (OA) animal model. CD105+-MSCs were injected twice into the OA monkeys with an interval of one week between them. The animals were euthanized one month after treatment. Immunohistochemistry analysis of different organs: spleen, heart, fat, liver, gut, pancreas, lung, skeletal muscle and kidney from the animals revealed that CD105+-MSCs migrated towards the injured knee joint. MSCs naive were found statistically significant increased in the injured knee in front of healthy one. CD105+-MSCs were negatives for CD68 and the area where CD105+-MSCs were found presented SDF-1 increased levels in front of healthy knee. We concluded that a characterized MSCs subset could be a safe alternative for cell therapy in clearly localized pathologies.


Osteoarthritis and Cartilage | 2009

172 CHARACTERIZATION OF microRNA EXPRESSION PROFILES IN NORMAL AND OSTEOARTHRITIC HUMAN CHONDROCYTES

Silvia Díaz-Prado; C. Cicione; E. Muiños; M.C. Arufe; I.M. Fuentes; F.J. De Toro; F.J. Blanco

entiation of both of them confirmed by staining with Oil Red O and Alizarin Red respectively. We carried out RT-PCR and immunohistochemistry analysis to test expression of SOX9, type II collagen, type I collagen and C-20 aggrecan which are proteoglycan compounds of extra-cellular matrix and all of them were positive as soon as after 4 days in culture. Expressions of type X collagen and MMP-13 proteins also were measured raising their expression as well as increase the time in culture.


World journal of orthopedics | 2011

Umbilical cord as a mesenchymal stem cell source for treating joint pathologies

María Arufe; Alexandre De la Fuente; I.M. Fuentes; Francisco J. de Toro; F.J. Blanco


Osteoarthritis and Cartilage | 2010

164 CHONDROGENIC POTENTIAL OF SUBPOPULATIONS OF CELLS EXPRESSING MESENCHYMAL STEM CELL MARKERS DERIVED FROM HUMAN SYNOVIAL MEMBRANES

M.C. Arufe; A. De la Fuente; S. Díaz; I.M. Fuentes; F.J. De Toro; F.J. Blanco


Proteómica: revista de la Sociedad Española de Proteómica | 2011

Proteome analysis during a new chondrogenesis model from mesenchymal stem cells of human umbilical cord stroma

A. de la Fuente González; Jesús Mateos; I. Lesende; Valentina Calamia; I.M. Fuentes; J. de Toro; M.C. Arufe; Francisco J. Blanco


Osteoarthritis and Cartilage | 2011

109 MESENCHYMAL STEM CELLS MIGRATE INTO OSTEOARTHRITIS JOINT FROM SYSTEMIC CIRCULATION: AN ANIMAL MODEL

M.C. Arufe; A. De la Fuente; Iván Lesende-Rodríguez; I.M. Fuentes; F.J. De Toro; F.J. Blanco


Osteoarthritis and Cartilage | 2011

475 CHONDROGENIC DIFFERENTIATION OF BONE MARROW MESENCHYMAL STEM CELLS (BM-MSCS) GROWN ON COLLAGEN POROUS SCAFFOLDS

Silvia Díaz-Prado; Emma Muiños-López; Tamara Hermida-Gómez; I.M. Fuentes; P. Esbrit; J. Buján; F.J. De Toro; F.J. Blanco

Collaboration


Dive into the I.M. Fuentes's collaboration.

Top Co-Authors

Avatar

F.J. Blanco

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

F.J. De Toro

University of A Coruña

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge